Invigo advised Sanofi Pasteur SA with regard to its participation as Project Leader in DRIVE, a public-private funded consortium initiated by the Innovative Medicines Initiative 2, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The DRIVE project aims to carry out joint influenza vaccine effectiveness studies. Influenza remains one of the top 10 infectious diseases worldwide and among the leading causes of hospitalization and death due to infectious diseases in developed nations. The project strives at achieving a strengthened capacity in Europe to monitor the effectiveness of the yearly seasonal influenza vaccines and to generate effectiveness data across age, causing benefits for manufacturers as well as the public health sector, and ultimately Europe’s citizens.